<div id="readability-page-1"><p>Evotec (NASDAQ:EVO - Get Free Report) will likely be posting its  Q4 2025 resultson Wednesday, May 6th. Analysts expect Evotec to post earnings of ($0.1220) per share and revenue of $263.1310 million for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 8:00 AM ET.</p><ul><li>Why These 3 Large Caps Are Bucking the August Slump</li></ul><p>Evotec (NASDAQ:EVO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $297.02 million during the quarter. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%. On average, analysts expect Evotec to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>Evotec Trading Down 0.5%</h2><p>Shares of NASDAQ:EVO traded down $0.02 during trading on Wednesday, hitting $2.97. The company had a trading volume of 1,169 shares, compared to its average volume of 135,420. Evotec has a one year low of $2.31 and a one year high of $4.80. The company has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $3.24. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99. </p><h2>Institutional Investors Weigh In On Evotec</h2><p>Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in shares of  Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after acquiring an additional 4,600 shares during the last quarter.  Bank of America Corp DE lifted its stake in shares of  Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter.  Marshall Wace LLP bought a new stake in shares of  Evotec during the 4th quarter worth approximately $40,000.  XTX Topco Ltd bought a new stake in shares of  Evotec during the 2nd quarter worth approximately $66,000.  Finally, HRT Financial LP bought a new stake in shares of  Evotec during the 4th quarter worth approximately $72,000. 5.81% of the stock is owned by institutional investors. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have recently issued reports on the company. Weiss Ratings raised Evotec from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a research note on Friday. Berenberg Bank assumed coverage on Evotec in a research note on Tuesday, February 3rd. They issued a &#34;buy&#34; rating for the company. Wall Street Zen raised Evotec from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, January 10th. Finally, HC Wainwright assumed coverage on Evotec in a research note on Wednesday, April 15th. They issued a &#34;buy&#34; rating and a $7.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, Evotec  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $7.00.</p><p><b>View Our Latest Report on EVO</b></p><h2>About Evotec</h2> (Get Free Report)<p>Evotec SE <span>NASDAQ: EVO<span></span></span> is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.  </p><p>Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.</p><h2>Read More</h2><ul><li>Five stocks we like better than Evotec</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVZP?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVZP"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Evotec Right Now?</h2><p>Before you consider Evotec, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.</p><p>While Evotec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABU

LABD

<p>Evotec (NASDAQ:EVO) is set to release its Q4 2025 earnings on May 6, with analysts expecting a loss of $0.1220 per share and revenue of $263.131 million. The company reported $0.05 EPS and $297.02 million revenue in its last quarter. Shares traded down 0.5% to $2.97, with a one-year range of $2.31 to $4.80. Institutional investors have increased their stakes, and analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $7.00.</p>

Market Beat

Evotec SE

Direxion S&P Biotech Bull 3X

Direxion S&P Biotech Bear 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

BNP Paribas

Bank of America

Healthcare Realty Trust

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Evotec (EVO) to Release Quarterly Earnings on Wednesday